Article
Medical Laboratory Technology
Maibritt Norgaard, Marianne T. Bjerre, Jacob Fredsoe, Soren Vang, Jorgen B. Jensen, Bram De Laere, Henrik Groenberg, Michael Borre, Johan Lindberg, Karina D. Sorensen
Summary: The clinical utility of low-pass whole-genome sequencing (LPWGS) of circulating tumor DNA (ctDNA) for prognostication in metastatic castration-resistant prostate cancer (mCRPC) was examined. The study found that high ctDNA% and high copy number alteration (CNA) burden at baseline were associated with poor treatment response, progression-free survival (PFS), and overall survival (OS). These findings were confirmed in an independent cohort.
CLINICAL CHEMISTRY
(2023)
Article
Oncology
Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stephane Oudard, Felix Y. Feng, Yashoda Rajpurohit, Karen Urtishak, Deborah S. Ricci, Brendan Rooney, Angela Lopez-Gitlitz, Margaret Yu, Alexander W. Wyatt, Mark Li, Gerhardt Attard, Eric J. Small
Summary: The SPARTAN study showed that adding apalutamide to ADT improved survival outcomes in nmCRPC patients, but resistance mechanisms need further evaluation. Detectable ctDNA, AR aberrations, and TP53/BRCA2 inactivation at EOST were significantly associated with poor outcomes in patients who received first subsequent androgen signaling inhibitor treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jian Pan, Jinou Zhao, Xudong Ni, Bin Zhu, Xiaoxin Hu, Qifeng Wang, Yu Wei, Tingwei Zhang, Hualei Gan, Beihe Wang, Junlong Wu, Shaoli Song, Chang Liu, Dingwei Ye, Yao Zhu
Summary: The study aimed to evaluate the impact of the spatial heterogeneity of PSMA uptake on ctDNA characteristics and the response rate to NHA treatment. This retrospective study included 153 mCRPC patients who underwent Ga-68 Ga-PSMA-11 PET/CT and ctDNA sequencing. The results showed that higher SUVhetero values were associated with higher ctDNA proportions. English Summary: The spatial heterogeneity of PSMA uptake is closely related to ctDNA characteristics and the response rate to NHA treatment.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Samuel R. Denmeade, Hao Wang, Neeraj Agarwal, David C. Smith, Michael T. Schweizer, Mark N. Stein, Vasileios Assikis, Przemyslaw W. Twardowski, Thomas W. Flaig, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Ralph J. Hauke, Guru Sonpavde, Jorge A. Garcia, Arif Hussain, Oliver Sartor, Shifeng Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Bolejack, Channing J. Paller, Michael A. Carducci, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis
Summary: Bipolar androgen therapy (BAT) shows meaningful clinical activity and safety in prostate cancer patients, suggesting it could be an effective treatment approach. The study results indicate that BAT can enhance sensitivity to enzalutamide, potentially improving survival in castration-resistant prostate cancer patients.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Takeshi Ashizawa, Masayoshi Nagata, So Nakamura, Hisashi Hirano, Naoya Nagaya, Yan Lu, Shigeo Horie
Summary: In this study, the effectiveness of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) was evaluated. The results showed that the expression of AR-V7 was not associated with cabazitaxel sensitivity, and reductions in bone scan index (BSI) and prostate-specific antigen (PSA) during early stages of cabazitaxel treatment may predict overall survival (OS) in patients.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Jacob J. Orme, Lance C. Pagliaro, J. Fernando Quevedo, Sean S. Park, Brian A. Costello
Summary: This report provides a comprehensive overview of the evidence and rational sequencing strategies for the use of second-generation antiandrogens in prostate cancer treatment. It highlights the growing list of approvals and indications for these drugs and suggests a prioritization sequence for their use in different stages of the disease. The report concludes that an optimized sequencing of second-generation antiandrogens with other treatment options is feasible based on current data.
Article
Oncology
Rana R. McKay, Lucia Kwak, Jett P. Crowdis, Jamie M. Sperger, Shuang G. Zhao, Wanling Xie, Lillian Werner, Rosina T. Lis, Zhenwei Zhang, Xiao X. Wei, Joshua M. Lang, Eliezer M. Van Allen, Rupal S. Bhatt, Evan Y. Yu, Peter S. Nelson, Glenn J. Bubley, R. Bruce Montgomery, Mary-Ellen Taplin
Summary: Enzalutamide has shown improved overall survival in metastatic CRPC, but resistance eventually develops. This study found baseline and progression alterations in AR pathway and tumor suppressor genes in a large proportion of patients. Post-enzalutamide, there was an increase in BRCA2 alterations, emphasizing the importance of serial tumor sampling in CRPC.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Jingsong Zhang, Jill Gallaher, Jessica J. Cunningham, Jung W. Choi, Filip Ionescu, Monica S. Chatwal, Rohit Jain, Youngchul Kim, Liang Wang, Joel S. Brown, Alexander R. Anderson, Robert A. Gatenby
Summary: This study proposes an individualized treatment strategy based on the dynamic response of prostate-specific antigen (PSA) levels in metastatic prostate cancer patients. The use of new hormonal agents combined with on-and-off androgen deprivation therapy (ADT) showed better cancer control and potentially improved survival rates. The feasibility of this adaptive therapy is demonstrated, providing a foundation for future randomized controlled studies in metastatic prostate cancer.
Article
Oncology
Dae-Hwan Kim, Duanchen Sun, William K. Storck, Katherine Welker Leng, Chelsea Jenkins, Daniel J. Coleman, David Sampson, Xiangnan Guan, Anbarasu Kumaraswamy, Eva S. Rodansky, Joshua A. Urrutia, Jacob A. Schwartzman, Chao Zhang, Himisha Beltran, Mark P. Labrecque, Colm Morrissey, Jared M. Lucas, Ilsa M. Coleman, Peter S. Nelson, Eva Corey, Samuel K. Handelman, Jonathan Z. Sexton, Rahul Aggarwal, Wassim Abida, Felix Y. Feng, Eric J. Small, Daniel E. Spratt, Armand Bankhead, Arvind Rao, Emily M. Gesner, Sarah Attwell, Sanjay Lakhotia, Eric Campeau, Joel A. Yates, Zheng Xia, Joshi J. Alumkal
Summary: NEPC is the most aggressive lineage plasticity in prostate cancer, with limited treatment options. By inhibiting AR and using BET inhibitors, it is possible to block this lineage plasticity, showing promising potential for t-NEPC treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Peng-Fei Zhang, Dan Xie, Qiu Li
Summary: From the US payer's perspective, cabazitaxel may not be a cost-effective treatment option compared to androgen-signaling-targeted inhibitors for patients with mCRPC who had progression within 12 months while receiving ASTIs after docetaxel treatment.
Review
Oncology
Georges Gebrael, Gliceida Galarza Fortuna, Nicolas Sayegh, Umang Swami, Neeraj Agarwal
Summary: The field of metastatic prostate cancer has witnessed significant therapeutic advances in the past decade, with recent approvals of triplet therapy regimens and combination therapies. However, treatment selection and sequencing remain challenging.
Article
Oncology
Axel S. Merseburger, Gerhardt Attard, Lennart astroem, Vsevolod B. Matveev, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elzbieta Senkus, Marta Lopez-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Summary: The study found that continuing enzalutamide with docetaxel and androgen deprivation therapy can delay progression in men with mCRPC, supporting the idea that enzalutamide maintenance may control persistent androgen-dependent clones.
Article
Oncology
Santosh Gupta, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, Andrew J. Armstrong
Summary: This study identified common genomic alterations in CTCs from AR-V7-negative mCRPC men associated with poor outcomes during enzalutamide/abiraterone treatment. The alterations were linked to lineage plasticity, epigenetic signaling, DNA repair, AR, TP53/RB1, PTEN, and WNT pathways.
MOLECULAR CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Yi-Ting Lin, Yen-Chun Huang, Chih-Kuan Liu, Tian-Shyug Lee, Mingchih Chen, Yu-Ning Chien
Summary: Secondary hormone therapy with abiraterone and enzalutamide has significantly improved outcomes for mCRPC patients. Enzalutamide was found to be superior to abiraterone in terms of overall survival, and there was no statistically significant difference in the development of new comorbidities between the two groups. The Charlson comorbidity index score, rather than individual items, was a statistically significant predictor for overall survival.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Maryam Soleimani, Kevin Zou, Katherine Sunderland, Werner Struss, Bernie J. Eigl, Lucia Nappi, Christian K. Kollmannsberger, Daygen Finch, Krista Noonan, Joanna Vergidis, Muhammad Zulfiqar, Kim N. Chi, Daniel J. Khalaf
Summary: A comparison study of AA and enzalutamide in patients with mCRPC aged >= 80 years showed that enzalutamide had a higher PSA response rate and longer time to progression, although there were more dose reductions and treatment discontinuations in the enzalutamide group.
EUROPEAN JOURNAL OF CANCER
(2021)
Editorial Material
Cardiac & Cardiovascular Systems
Ruth-Alma Turkson-Ocran, Kathryn Foti, Anika L. Hines, Debora Kamin Mukaz, Hyunju Kim, Samantha Martin, Anum Minhas, Faye L. Norby, Oluwabunmi Ogungbe, Alexander C. Razavi, Mary R. Rooney, Elisabeth L. P. Sattler, Jewel Scott, Alvin G. Thomas, Curtis Tilves, Amelia S. Wallace, Frances M. Wang, Mingyu Zhang, Pamela L. Lutsey, Kristie J. Lancaster
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Letter
Hematology
Melissa C. Caughey, Vimal K. Derebail, Marcus A. Carden, Enrico M. Novelli, Pamela L. Lutsey, Nigel S. Key, Abhijit V. Kshirsagar, Gerardo Heiss
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Geriatrics & Gerontology
Kelsie M. Full, Snigdha Pusalavidyasagar, Priya Palta, Kevin J. Sullivan, Jung-Im Shin, Rebecca F. Gottesman, Adam P. Spira, Matthew P. Pase, Pamela L. Lutsey
Summary: This study aimed to examine the association between the use of sleep medications and incident dementia in a community-based cohort of older adults. The results showed that sleep medication use was associated with a 48% greater risk of dementia compared to nonuse.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2023)
Article
Clinical Neurology
Sanaz Sedaghat, Pamela L. Lutsey, Yuekai Ji, Jean-Philippe Empana, Farzaneh Sorond, Timothy M. Hughes, Thomas H. Mosley, Rebecca F. Gottesman, David S. Knopman, Keenan A. Walker, Vilmundur Gudnason, Lenore J. Launer, Thomas T. van Sloten
Summary: Better cardiovascular health at midlife and improvement of cardiovascular health within midlife are associated with lower dementia risk.
ALZHEIMERS & DEMENTIA
(2023)
Article
Endocrinology & Metabolism
Brian T. Steffen, Weihong Tang, Pamela L. Lutsey, Ryan T. Demmer, Elizabeth Selvin, Kunihiro Matsushita, Alanna C. Morrison, Weihua Guan, Mary R. Rooney, Faye L. Norby, Nathan Pankratz, David Couper, James S. Pankow
Summary: Proteomics analysis identified plasma proteins associated with the risk of type 2 diabetes. These proteins may serve as potential targets for intervention or pharmacological approaches to prevent, reverse, or slow down the progression of type 2 diabetes.
Review
Cardiac & Cardiovascular Systems
Pamela L. Lutsey, Neil A. Zakai
Summary: Venous thromboembolism is an under-appreciated vascular disease with significant health disparities in incidence and outcomes. In addition to understanding the epidemiological characteristics and risk factors of this disease, attention should also be given to prevention measures and reducing disparities.
NATURE REVIEWS CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Xiao Hu, Yejin Mok, Ning Ding, Kevin J. Sullivan, Pamela L. Lutsey, Jennifer A. Schrack, Priya Palta, Kunihiro Matsushita
Summary: Reduced physical function is independently associated with the risk of composite and individual CVD outcomes and improves their risk prediction beyond traditional risk factors in community-dwelling older adults.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Hematology
Brian T. Steffen, James S. Pankow, Faye L. Norby, Pamela L. Lutsey, Ryan T. Demmer, Weihua Guan, Nathan Pankratz, Aixin Li, Guning Liu, Kunihiro Matsushita, Adrienne Tin, Weihong Tang
Summary: This study identified proteomic signatures and pathways related to 23 gene loci associated with abdominal aortic aneurysm (AAA). The results suggest that low levels of neogenin and kit ligand may be novel risk factors for AAA development.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Arun Kumar, Pamela L. Lutsey, Wendy L. St. Peter, Jon C. Schommer, Jeremy R. Van't Hof, Abhijeet Rajpurohit, Joel F. Farley
Summary: In acute coronary syndrome following percutaneous coronary intervention, newer P2Y12 inhibitors (ticagrelor and prasugrel) reduce cardiovascular outcomes compared to clopidogrel, but have a higher bleeding risk. This study examines the safety of each inhibitor in a real-world population.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Pharmacology & Pharmacy
Arun Kumar, Pamela L. Lutsey, Wendy L. St Peter, Jon C. Schommer, Jeremy R. Van't Hof, Abhijeet Rajpurohit, Joel F. Farley
Summary: This study compared the effectiveness of newer P2Y12 inhibitors (prasugrel and ticagrelor) with clopidogrel in real-world US populations. The results showed that ticagrelor reduced the risk of cardiovascular events by 10% at 90 days compared to clopidogrel. There were no significant differences for other comparisons. This study provides valuable information for clinicians in selecting P2Y12 inhibitors after ACS.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biochemical Research Methods
Bruno Bohn, Pamela L. Lutsey, Weihong Tang, James S. Pankow, Faye L. Norby, Bing Yu, Christie M. Ballantyne, Eric A. Whitsel, Kunihiro Matsushita, Ryan T. Demmer
Summary: This study compared the proteome of statin users and nonusers and found differences in proteins unrelated to lipid metabolism. Further investigation into these differences may help elucidate the pleiotropic effects of statins.
JOURNAL OF PROTEOMICS
(2023)
Article
Medicine, General & Internal
Bruno Bohn, Pamela L. Lutsey, Jeffrey R. Misialek, Keenan A. Walker, Charles H. Brown, Timothy M. Hughes, Junichi Ishigami, Kunihiro Matsushita, Ryan T. Demmer
Summary: This study found an association between hospitalization with infection and incident dementia, suggesting that infections are risk factors for dementia.
Article
Nutrition & Dietetics
Linzi Li, Pamela L. Lutsey, Lin Yee Chen, Elsayed Z. Soliman, Mary R. Rooney, Alvaro Alonso
Summary: Higher serum magnesium is associated with a lower risk of cardiovascular events, especially myocardial infarction, in patients with atrial fibrillation.
Article
Hematology
Pamela L. Lutsey
Summary: The case-control design is an observational study design that compares the exposure prevalence between individuals with and without disease. Proper control selection is crucial for case-control study design, and optimizing control selection can maximize causal inference and enhance the scientific rigor of hematologic case-control studies.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Respiratory System
David M. MacDonald, Yuekai Ji, Selcuk Adabag, Alvaro Alonso, Lin Yee Chen, Benjamin E. Henkle, Stephen P. Juraschek, Faye L. Norby, Pamela L. Lutsey, Ken M. Kunisaki
Summary: This study found that better cardiovascular autonomic function was associated with a lower risk of COPD hospitalization, while worse autonomic function was associated with a higher risk of COPD hospitalization. This relationship was more significant in participants without airflow obstruction.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2023)